AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC

PHASE2

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Stopped In view of the recent developments in the field (the increasing number of trials with new KRAS inhibitors), the window of opportunity to answer the question raised in the AMBER trial was missed.

Conditions

Metastatic Non Small Cell Lung Cancer
KRAS G12C

Interventions

DRUG: Sotorasib
DRUG: Lenvatinib

Sponsor

ETOP IBCSG Partners Foundation

Collaborators

[object Object]
[object Object]